REVIEW article

Front. Oncol.

Sec. Cancer Molecular Targets and Therapeutics

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1593774

This article is part of the Research TopicThe Role of Nod-Like Receptor (NLR) Family of Proteins in InflammationView all 5 articles

The NLRP3 Inflammasome in Urogenital Cancers: Structure, Dual Function, and Therapeutic Potential

Provisionally accepted
  • 1First Hospital of Lanzhou University, Lanzhou, Gansu Province, China
  • 2Lanzhou University Medical College, Lanzhou, Gansu, China

The final, formatted version of the article will be published soon.

The NLRP3 inflammasome is a multi-subunit complex consisting of the NLRP3 receptor protein, apoptosis-associated speck-like protein (ASC), and the effector protein caspase-1. The activation mechanisms of the NLRP3 inflammasome are diverse and complex, primarily involving both classical and non-classical pathways. The activation process is generally considered to occur in two stages: the first, "priming," which involves the initial immune signaling trigger, followed by the second stage, "activation," during which further signaling leads to the formation and functional activation of the NLRP3 inflammasome. Upon activation, the NLRP3 inflammasome activates caspase-1, triggering the maturation and release of downstream pro-inflammatory cytokines, such as IL-18 and IL-1β, which in turn promote the inflammatory response. In recent years, an increasing body of research has highlighted the close association between the NLRP3 inflammasome and its downstream signaling pathways with the development and progression of urogenital system cancers. These studies suggest that the NLRP3 inflammasome may serve as a potential therapeutic target, holding significant clinical application value in cancer treatment. Despite the growing number of related studies, a comprehensive and systematic review summarizing the role of the NLRP3 inflammasome in urogenital cancers and its potential therapeutic strategies is still lacking. This review aims to provide an extensive overview of the composition and activation mechanisms of the NLRP3 inflammasome, explore its involvement in urogenital system cancers, delve into related targeted therapy strategies, and discuss future research directions, with the goal of offering valuable insights for researchers in this field.

Keywords: NLRP3, Inflammasome, urogenital cancer, Activation mechanism, targeted therapy

Received: 14 Mar 2025; Accepted: 20 Jun 2025.

Copyright: © 2025 Sun, Ma, Zhao, Tian and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Weiming Sun, First Hospital of Lanzhou University, Lanzhou, Gansu Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.